Current Assets
Accounts Receivable
Gilead Sciences Accounts Receivable decreased by 6.0% to $5.54B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.5%, from $5.26B to $5.54B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows relatively stable performance with a 1.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase relative to revenue may signal collection issues or aggressive sales tactics, while a decrease suggests efficient cash conversion.
Detailed definition
This represents the balance of money owed to the company by customers for goods or services delivered, adjusted for expe...
Peer comparison
Standard across all industries; comparable to other large-cap pharmaceutical firms with similar distribution networks.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.91B | $5.28B | $5.28B | $4.56B | $4.9B | $5.01B | $5.46B | $4.93B | $5.05B | $5.59B | $5.5B | $5.52B | $5.49B | $5.46B | $5.32B | $5.26B | $5.62B | $5.99B | $5.9B | $5.54B |
| QoQ Change | — | +7.7% | -0.1% | -13.6% | +7.5% | +2.1% | +9.1% | -9.7% | +2.4% | +10.6% | -1.6% | +0.4% | -0.6% | -0.4% | -2.6% | -1.2% | +7.0% | +6.6% | -1.7% | -6.0% |
| YoY Change | — | — | — | — | -0.1% | -5.3% | +3.5% | +8.2% | +3.0% | +11.6% | +0.6% | +11.9% | +8.7% | -2.2% | -3.2% | -4.8% | +2.5% | +9.7% | +10.8% | +5.5% |
Range$4.56B – $5.99B
CAGR+2.6%
Avg YoY Growth+3.8%
Median YoY Growth+3.3%
Current Streak2 quarters decline
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's accounts receivable?
- Gilead Sciences (GILD) reported accounts receivable of $5.54B in Q1 2026.
- How has Gilead Sciences's accounts receivable changed year-over-year?
- Gilead Sciences's accounts receivable increased by 5.5% year-over-year, from $5.26B to $5.54B.
- What is the long-term trend for Gilead Sciences's accounts receivable?
- Over 5 years (2020 to 2025), Gilead Sciences's accounts receivable has grown at a 1.2% compound annual growth rate (CAGR), from $5.56B to $5.9B.
- What does accounts receivable mean?
- The amount of money customers owe the company for products already delivered.